Research analysts at BTIG Research began coverage on shares of Trillium Therapeutics Inc. (NASDAQ:TRIL) in a research report issued to clients and investors on Thursday. The firm set a “buy” rating on the stock.

Several other brokerages have also recently issued reports on TRIL. Zacks Investment Research cut shares of Trillium Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, September 16th. Ladenburg Thalmann assumed coverage on shares of Trillium Therapeutics in a research report on Wednesday, August 3rd. They issued a “buy” rating and a $18.00 price target for the company. Leerink Swann restated an “outperform” rating and issued a $20.00 price target on shares of Trillium Therapeutics in a research report on Monday, August 15th. Finally, Cowen and Company restated a “buy” rating on shares of Trillium Therapeutics in a research report on Sunday, June 12th. Six equities research analysts have rated the stock with a buy rating, Trillium Therapeutics has a consensus rating of “Buy” and an average price target of $22.75.

Analyst Recommendations for Trillium Therapeutics (NASDAQ:TRIL)

Shares of Trillium Therapeutics (NASDAQ:TRIL) opened at 16.63 on Thursday. The firm’s market capitalization is $129.95 million. Trillium Therapeutics has a one year low of $6.62 and a one year high of $17.70. The company’s 50 day moving average is $14.10 and its 200-day moving average is $11.04.

Several large investors have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its stake in Trillium Therapeutics by 5.7% in the first quarter. Renaissance Technologies LLC now owns 25,478 shares of the company’s stock worth $236,000 after buying an additional 1,380 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new stake in Trillium Therapeutics during the first quarter worth approximately $100,000. Sabby Management LLC purchased a new stake in Trillium Therapeutics during the first quarter worth approximately $131,000. K2 Principal Fund L.P. purchased a new stake in Trillium Therapeutics during the second quarter worth approximately $131,000. Finally, Point72 Asset Management L.P. raised its stake in Trillium Therapeutics by 8.6% in the second quarter. Point72 Asset Management L.P. now owns 369,300 shares of the company’s stock worth $3,316,000 after buying an additional 29,300 shares in the last quarter. 39.34% of the stock is currently owned by institutional investors.

5 Day Chart for NASDAQ:TRIL

Receive News & Stock Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related stocks with our FREE daily email newsletter.